

In the Claims:

Please cancel claims 14-63, 68 and 69 without prejudice.

Please amend claims 64, 66 and 68-70 as follows:

1-63. (Canceled)

64. (Currently Amended) An isolated protein having heparanase catalytic (endo- β -D-glucuronidase) activity or being cleavable so as to acquire said heparanase catalytic activity, said protein including a polypeptide at least 60% 90% homologous to SEQ ID NO: 10 or a portion thereof, said protein being capable of eliciting an anti-heparanase antibody.

65. (Currently Amended) A pharmaceutical composition comprising, as an active ingredient, the isolated protein of claim ~~62~~ 64, and a pharmaceutically acceptable carrier.

66. (Currently Amended) A preparation comprising a protein having heparanase (endo- β -D-glucuronidase) catalytic activity or being cleavable so as to acquire said heparanase catalytic activity, said protein including a polypeptide at least 60% 90% homologous to SEQ ID NO: 10 or a portion thereof.

67. (Previously Presented) The preparation of claim 66, wherein said polypeptide is characterized by being recombinant.

68-69. (Canceled)

70. (Currently Amended) A preparation comprising a recombinant protein having heparanase (endo- β -D-glucuronidase) catalytic activity or being cleavable so as to acquire said heparanase catalytic activity, said protein being characterized by being about 50 or about 65 kDa, and said protein being characterized by being capable of being purified with a purification procedure initiated with Heparin-Sepharose chromatography, followed by gel filtration and pooling of active column fractions, wherein a quantity of said protein after said purification correlates with heparanase activity in said pooled active column fractions, said protein being at least ~~60%~~ 90% homologous to SEQ ID NO: 10 or a portion thereof.

Please add new claims 71-79 as follows:

71. (New) An isolated protein having heparanase catalytic (endo- β -D-glucuronidase) activity or being cleavable so as to acquire said heparanase catalytic activity, said protein including a polypeptide at least 95% homologous to SEQ ID NO: 10 or a portion thereof, said protein being capable of eliciting an anti-heparanase antibody.

72. (New) A pharmaceutical composition comprising, as an active ingredient, the isolated protein of claim 71, and a pharmaceutically acceptable carrier.

73. (New) An isolated, recombinant protein having heparanase catalytic (endo- β -D-glucuronidase) activity or being cleavable so as to acquire said heparanase catalytic activity, said protein including a polypeptide at least 90% homologous to SEQ ID NO: 10 or a portion thereof.

74. (New) The protein of claim 73, wherein said protein includes a polypeptide at least 95% homologous to SEQ ID NO: 10 or a portion thereof.
75. (New) A pharmaceutical composition comprising, as an active ingredient, the isolated protein of claim 73, and a pharmaceutically acceptable carrier.
76. (New) A recombinant protein having heparanase catalytic (endo- β -D-glucuronidase) activity or being cleavable so as to acquire said heparanase catalytic activity, said protein being purified close to homogeneity and said protein including a polypeptide at least 90% homologous to SEQ ID NO: 10 or a portion thereof.
77. (New) The protein of claim 76, wherein said protein includes a polypeptide at least 95% homologous to SEQ ID NO: 10 or a portion thereof.
78. (New) A pharmaceutical composition comprising, as an active ingredient, the protein of claim 76, and a pharmaceutically acceptable carrier.
79. (New) The preparation of claim 70, wherein said protein is at least 95% homologous to SEQ ID NO: 10 or a portion thereof.